PortalPublikationenComplement Inhibitors in Clinical Trials for Glomerular Dise...

Complement Inhibitors in Clinical Trials for Glomerular Diseases

Standard

Complement Inhibitors in Clinical Trials for Glomerular Diseases. / Zipfel, Peter F; Wiech, Thorsten; Rudnick, Ramona; Afonso, Sara; Person, Fermin; Skerka, Christine.

in: FRONT IMMUNOL, Jahrgang 10, 2019, S. 2166.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Zipfel, PF, Wiech, T, Rudnick, R, Afonso, S, Person, F & Skerka, C 2019, 'Complement Inhibitors in Clinical Trials for Glomerular Diseases', FRONT IMMUNOL, Jg. 10, S. 2166. https://doi.org/10.3389/fimmu.2019.02166

APA

Zipfel, P. F., Wiech, T., Rudnick, R., Afonso, S., Person, F., & Skerka, C. (2019). Complement Inhibitors in Clinical Trials for Glomerular Diseases. FRONT IMMUNOL, 10, 2166. https://doi.org/10.3389/fimmu.2019.02166

Vancouver

Zipfel PF, Wiech T, Rudnick R, Afonso S, Person F, Skerka C. Complement Inhibitors in Clinical Trials for Glomerular Diseases. FRONT IMMUNOL. 2019;10:2166. https://doi.org/10.3389/fimmu.2019.02166

Bibtex

@article{07ee4545043240c6a01adae251270f4d,
title = "Complement Inhibitors in Clinical Trials for Glomerular Diseases",
abstract = "Defective complement action is a cause of several human glomerular diseases including atypical hemolytic uremic syndrome (aHUS), anti-neutrophil cytoplasmic antibody mediated vasculitis (ANCA), C3 glomerulopathy, IgA nephropathy, immune complex membranoproliferative glomerulonephritis, ischemic reperfusion injury, lupus nephritis, membranous nephropathy, and chronic transplant mediated glomerulopathy. Here we summarize ongoing clinical trials of complement inhibitors in nine glomerular diseases and show which inhibitors are used in trials for these renal disorders (http://clinicaltrials.gov).",
author = "Zipfel, {Peter F} and Thorsten Wiech and Ramona Rudnick and Sara Afonso and Fermin Person and Christine Skerka",
note = "Copyright {\textcopyright} 2019 Zipfel, Wiech, Rudnick, Afonso, Person and Skerka.",
year = "2019",
doi = "10.3389/fimmu.2019.02166",
language = "English",
volume = "10",
pages = "2166",
journal = "FRONT IMMUNOL",
issn = "1664-3224",
publisher = "Lausanne : Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Complement Inhibitors in Clinical Trials for Glomerular Diseases

AU - Zipfel, Peter F

AU - Wiech, Thorsten

AU - Rudnick, Ramona

AU - Afonso, Sara

AU - Person, Fermin

AU - Skerka, Christine

N1 - Copyright © 2019 Zipfel, Wiech, Rudnick, Afonso, Person and Skerka.

PY - 2019

Y1 - 2019

N2 - Defective complement action is a cause of several human glomerular diseases including atypical hemolytic uremic syndrome (aHUS), anti-neutrophil cytoplasmic antibody mediated vasculitis (ANCA), C3 glomerulopathy, IgA nephropathy, immune complex membranoproliferative glomerulonephritis, ischemic reperfusion injury, lupus nephritis, membranous nephropathy, and chronic transplant mediated glomerulopathy. Here we summarize ongoing clinical trials of complement inhibitors in nine glomerular diseases and show which inhibitors are used in trials for these renal disorders (http://clinicaltrials.gov).

AB - Defective complement action is a cause of several human glomerular diseases including atypical hemolytic uremic syndrome (aHUS), anti-neutrophil cytoplasmic antibody mediated vasculitis (ANCA), C3 glomerulopathy, IgA nephropathy, immune complex membranoproliferative glomerulonephritis, ischemic reperfusion injury, lupus nephritis, membranous nephropathy, and chronic transplant mediated glomerulopathy. Here we summarize ongoing clinical trials of complement inhibitors in nine glomerular diseases and show which inhibitors are used in trials for these renal disorders (http://clinicaltrials.gov).

U2 - 10.3389/fimmu.2019.02166

DO - 10.3389/fimmu.2019.02166

M3 - SCORING: Review article

C2 - 31611870

VL - 10

SP - 2166

JO - FRONT IMMUNOL

JF - FRONT IMMUNOL

SN - 1664-3224

ER -